Good news, Time Warner (NYSE: TWX ) investors. After suffering a run of bad numbers, buzz is finally building for Pacific Rim, director Guillermo Del Toro's giant robots vs. monsters epic that cost as much as $200 million to make.
Plenty is it stake for Warner and financing partner Legendary Pictures, says Fool contributor Tim Beyers in the following video. Why? Both studios need a new franchise to bank on. The fact that 75% of critics who've seen Pacific Rim rate it as "fresh"-- better than the 67% accorded to surprise hit World War Z -- suggests the film could enjoy a decent run in theaters.
But will it be as big a winner as the zombie thriller? According to Box Office Mojo, Viacom's (NASDAQ: VIAB ) Paramount Studios has earned more than $370 million in worldwide grosses from the film, which has enjoyed uncommon staying power after last weekend's gate drop of just 38%, when 50% or more is typical. Getting even within spitting distance of that performance would be a win for Del Toro, Legendary, and Time Warner investors, Tim says.
Do you like the odds of Pacific Rim outperforming? Please watch the video to get Tim's full take, and then leave a comment to let us know whether you plan to see the film.
Top 10 Performing Companies To Invest In 2014: Imax Corp Com Npv(IMX.TO)
IMAX Corporation, together with its subsidiaries, operates as an entertainment technology company specializing in motion picture technologies and presentations worldwide. The company operates in seven segments: IMAX Systems, Theater System Maintenance, Joint Revenue Sharing Arrangements, Film Production and IMAX Digital Re-Mastering (DRM), Film Distribution, Film Post-Production, and Other. The IMAX Systems segment designs, manufactures, sells, or leases IMAX theater projection system equipment. The Theater System Maintenance segment maintains IMAX theater projection system equipment in the IMAX theater network. The Joint Revenue Sharing Arrangements segment provides IMAX theater projection system equipment to an exhibitor in exchange for a share of the box-office and concession revenues. The Film Production and IMAX DMR segment produces films and performs film re-mastering services. The Film Distribution segment distributes films for which the company has distribution rig hts. The Film Post-Production segment offers film post-production and film print services. The Other segment owns and operates IMAX theaters; rents two-dimensional and three-dimensional (3D) large-format film and digital cameras to third party production companies; and offers after market sales services for projection system parts and 3D glasses. The company serves institutional customers, such as science and natural history museums, zoos, aquaria, and other educational and cultural centers, as well as commercial multiplex exhibitors. IMAX Corporation also sells or leases its theater systems to theme parks, tourist destination sites, fairs, and expositions. As of December 31, 2011, the company operated 634 theater systems comprising 517 commercial and 117 institutional theater systems. IMAX Corporation was founded in 1967 and is headquartered in Mississauga, Canada.
Top 10 Performing Companies To Invest In 2014: Atlas Pearls and Perfumes Ltd (ATP.AX)
Atlas Pearls and Perfumes Ltd, formerly Atlas South Sea Pearl Ltd., is an Australia-based Company. The Company is engaged in the business of pearl production in Indonesia and distribution globally through the Company�� marketing operations in Australia. The Company also manufactures and sells pearl jewellery primarily in Bali, Indonesia. It segments include Wholesale Loose Pearl and Jewellery. Its wholesale business is a producer and supplier of pearls within the wholesale market. The retail business is the manufacture and sale of pearl jewellery and related products within the retail market. The Company's subsidiaries include Perl��co Pty Ltd, Tansim Pty Ltd, P.T. Cendana Indopearls and Aspirasi Satria Sdn Bhd.
Top 10 Growth Companies To Watch In Right Now: Parker Drilling Company(PKD)
Parker Drilling Company, together with its subsidiaries, provides contract drilling and drilling-related services in the United States, Latin America, Africa and the Middle East (AME), the Asia Pacific, and Commonwealth of Independent States (CIS). As of December 31, 2010, its fleet consisted of 11 rigs in the CIS/AME region; 10 rigs in the Americas region, including 7 land rigs and 1 barge rig in Mexico, and 2 land rigs in Colombia; 5 land rigs in the Asia Pacific region, including 2 rigs in Indonesia, 1 rig in Papua New Guinea, and 2 rigs in New Zealand; 13 barge drilling rigs in the inland shallow waters of the U.S. Gulf of Mexico; and 1 unassigned land rig held in New Iberia, Louisiana. The company also offers premium rental tools, including drill pipe, drill collars, tubing, high- and low-pressure blowout preventers, choke manifolds, junk and cement mills, and casing scrapers for land and offshore oil and gas drilling and workover activities. In addition, it provides non-capital intensive services, such as front end engineering and design; engineering, procurement, construction, and installation; operations and maintenance; and other project management services, which include labor, maintenance, and logistics for operators who own their own drilling rigs. The company serves independent and national oil and gas companies, and integrated service providers. Parker Drilling Company was founded in 1934 and is headquartered in Houston, Texas.
Advisors' Opinion:- [By Vita]
Parker Drilling Company is a provider of contract drilling and drilling-related services. Its EPS forecast for the current year is 0.3 and next year is 0.54. According to consensus estimates, its topline is expected to decline 3% current year and 26.66% next year. It is trading at a forward P/E of 12.99. Out of four analysts covering the company, two are positive and have buy recommendations and two have hold ratings.
Top 10 Performing Companies To Invest In 2014: The Spectranetics Corporation (SPNC)
The Spectranetics Corporation designs, manufactures, and markets single use medical devices used in minimally invasive surgical procedures within the cardiovascular system in conjunction with its proprietary excimer laser system, the CVX-300. The company?s excimer laser technology is used to ablate multiple lesion morphology morphologies, such as plaque, moderate calcium, and thrombus. It offers four primary product categories for the Vascular Intervention product line, including peripheral atherectomy, coronary atherectomy, thrombus management, and crossing solutions. The peripheral atherectomy product line consists of a selection of proprietary laser catheters that are indicated for the treatment of infrainguinal (leg) stenoses and occlusions; and the coronary atherectomy product line includes a selection of proprietary laser catheters to be used in various types of coronary artery diseases comprising occluded saphenous vein bypass grafts, ostial lesions, long lesions, m oderately calcified stenoses, total occlusions traversable by guidewire, lesions, and restenosis. The thrombus management product line consists of three thrombus removal devices intended to remove fresh, soft thrombi, and emboli from vessels in the arterial system, as well as to address thrombotic occlusions in dialysis grafts and fistulae; and the crossing solutions product line support guidewires or other devices in facilitating vascular access in the arterial system to enable various types of interventions. The company?s lead management product line comprises excimer laser sheaths, non-laser sheaths, and cardiac lead management accessories for the removal of pacemaker and defibrillator cardiac leads. It sells its products in the United States, Canada, Europe, the Middle East, the Asia Pacific, Latin America, and Puerto Rico. The company has a strategic alliance with Kensey Nash Corporation. The Spectranetics Corporation was founded in 1984 and is based in Colorado Springs , Colorado.
Top 10 Performing Companies To Invest In 2014: Investors Capital Holdings Ltd.(ICH)
Investors Capital Holdings, Ltd., through its subsidiaries, provides various financial services in the United States. It provides broker-dealer services in support of trading and investment in securities, such as corporate stocks and bonds, the U.S. government securities, municipal bonds, mutual funds, and variable annuities, as well as variable life insurance, including provision of market information, Internet trading and portfolio tracking facilities, and records management. The company also offers investment advisory services, such as asset allocation and portfolio rebalancing services. Investors Capital Holdings, Ltd. was founded in 1995 and is based in Lynnfield, Massachusetts.
Top 10 Performing Companies To Invest In 2014: Copper Ridge Explorations Inc.(KRX.V)
Redtail Metals Corp. engages in identifying, acquiring, and developing copper, lead, and zinc mineral deposits in the Yukon, Canada. It principally focuses on the Clear Lake massive sulphide zinc-lead-silver project located in the Yukon and the Babine porphyry copper-gold project in British Columbia. The company was formerly known as Copper Ridge Explorations Inc. and changed its name to Redtail Metals Corp. on May 30, 2011. Redtail Metals Corp. was founded in 1983 and is headquartered in Vancouver, Canada.
Top 10 Performing Companies To Invest In 2014: InspireMD Inc (NSPR.A)
InspireMD, Inc., incorporated on February 29, 2008, is a medical device company. The Company is focusing on the development and commercialization of its stent platform technology, MGuard. MGuard provides embolic protection in stenting procedures by placing a micron mesh sleeve over a stent. Its initial products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The Company�� products include MGuard Coronary Plus Bio-Stable Mesh, MGuard Peripheral Plus Bio-Stable Mesh, MGuard Carotid Plus Bio-Stable Mesh and MGuard Coronary Plus Bio-Absorbable Drug-Eluting Mesh. Its initial MGuard Coronary products incorporated a stainless steel stent. The Company subsequently replaced this stainless steel platform with a more advanced cobalt-chromium based platform, which the Company refers to as the MGuard PrimeTM version of its MGuard Coronary. The Company operates in Germany through its wholly owned subsidiary InspireMD GmbH.
The Company focuses on applying its technology to develop additional products used for other vascular procedures, specifically carotid (the arteries that supply blood to the brain) and peripheral (other arteries) procedures. The MGuard stent is an embolic protection device based on a protective sleeve, which is constructed out of an ultra-thin polymer mesh and wrapped around the stent. The protective sleeve is comprised of a micron level fiber-knitted mesh, engineered in an optimal geometric configuration and designed for utmost flexibility while retaining strength characteristics of the fiber material.
MGuard - Coronary Applications
The Company�� MGuard Coronary with a bio-stable mesh and its MGuard Coronary with a drug-eluting mesh focuses on the treatment of coronary arterial disease. The Company�� first MGuard product, the MGuard Coronary with a bi o-stable mesh, is comprised of its mesh sleeve wrapped arou! n! d a bare-metal stent. The bio-absorbability of MGuard Coronary with a drug eluting bio-absorbable mesh is intended to improve upon the bio-absorbability of other drug-eluting stents, in light of the wide surface area of the mesh and the small diameter of the fiber.
MGuard - Carotid Applications
The Company focuses on marketing its mesh sleeve coupled with a self-expandable stent for use in carotid-applications. Expandable stent is a stent that expands without balloon dilation pressure or need of an inflation balloon. This product is under development, although the Company has temporarily delayed its development until additional funding is secured.
MGuard - Peripheral Applications
Peripheral Artery Disease, also known as peripheral vascular disease, is characterized by the accumulation of plaque in arteries in the legs, need for amputation of affected joints or even death, when untreated. Peripheral Artery Disease is treated either by trying to clear the artery of the blockage, or by implanting a stent in the affected area to push the blockage out of the way of normal blood flow.
The Company competes with Abbott Laboratories, Boston Scientific Corporation, Johnson & Johnson, Medtronic, Inc., The Sorin Group, Xtent, Inc., Cinvention AG, OrbusNeich, Biotronik SE & Co. KG, Svelte Medical Systems, Inc., Reva Inc. and Stentys SA.
Top 10 Performing Companies To Invest In 2014: VirnetX Holding Corp(VHC)
VirnetX Holding Corporation engages in developing and commercializing software and technology solutions for securing real-time communications over the Internet. Its software and technology solutions, which include secure domain name registry and GABRIEL Connection Technology, facilitate secure communications and create a secure environment for real-time communication applications, such as instant messaging, voice over Internet protocol, smart phones, eReaders, and video conferencing. The company focuses on commercializing its technology to original equipment manufacturers within the IP-telephony, mobility, fixed-mobile convergence, and unified communications markets. VirnetX Holding Corporation was founded in 2005 and is headquartered in Scotts Valley, California.
Advisors' Opinion:- [By Sy_Harding]
VirnetX Holding Corp Common St (AMEX:VHC): This equity had 11,198,740 shares sold short as of Aug 31st, as compared to 9,939,110 on Aug 15th, which represents a change of 1,259,630 shares, or 12.7%. Days to cover for this company is 5 and average daily trading volume is 2,172,693. About the equity: Virnetx Holding Corporation is developing and commercializing software and technology solutions for securing real-time communications over the Internet.
Top 10 Performing Companies To Invest In 2014: Sunesis Pharmaceuticals Inc.(SNSS)
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company?s principal product includes Vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It is conducting various clinical trials of Vosaroxin, including Phase II clinical trial, known as VALOR trial in combination with cytarabine for the treatment of patients with relapsed or refractory AML; and a Phase II clinical trial, known as REVEAL-1 in previously untreated patients of age 60 years or older, as well as completed a Phase II single-agent trial of Vosaroxin in patients with platinum-resistant ovarian cancer. In addition, the company is conducting a Phase II/III trial, known as the Less Intensive 1 in patients older than 60 years with AML or high-risk myelodysplastic syndrome. It has a license agreement with Dainippon Sumitomo Pharma Co. , Ltd. for the development and commercialization of Vosaroxin; a collaboration agreement with Millennium for the development of pan-Raf kinase inhibitor and one additional undisclosed kinase inhibitor program in oncology; and a collaboration agreement with Biogen Idec, Inc. to discover, develop, and commercialize small molecule inhibitors of a preclinical kinase inhibitor program in immunology. The company formerly known as, Mosaic Pharmaceuticals, Inc., was founded in 1998 and is headquartered in South San Francisco, California.
Top 10 Performing Companies To Invest In 2014: Lam Research Corporation(LRCX)
Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipments used in the fabrication of integrated circuits. The company offers etch products that remove portions of various films from the wafer in the creation of semiconductor devices. Its etch products include dielectric etch, conductor etch, three-dimensional integrated circuit etch, MEMS devices, CMOS image sensors, and power devices for etching process. Lam Research Corporation also provides wafer cleaning steps that comprise post-etch and post-strip cleans, and pre-diffusion and pre-deposition cleans; and single-wafer wet clean and plasma-based bevel clean systems. The company offers its products to semiconductor manufacturers. It operates in the United States, Europe, Taiwan, Korea, Japan, and the Asia Pacific. Lam Research Corporation was founded in 1980 and is headquartered in Fremont, California.
No comments:
Post a Comment